Reference number : GC-2017-Q3-00653, amendment number : , agreement type : G, recipient legal name : Wootton, K. Sarah (University of Guelph), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Engage Plus Grants for universities, program name french : Subvention d'engagement partenarial Plus pour les universités, program purpose english : Viruses engineered to express antigens to promote a protective immune response against a particular pathogen_x000D_
(vaccine), or to deliver a therapeutic gene (gene therapy) or to treat cancer (oncolytic virotherapy) are essential_x000D_
tools used in the prevention and treatment of diseases in humans and animals. However, a considerable_x000D_
impediment to the use of viruses as vaccines or therapeutic agents is the availability of efficient, scalable_x000D_
purification systems. The goal of this project is to build upon the process development expertise acquired_x000D_
during our initial NSERC Engage funded collaboration with Natrix Separations, in which we successfully_x000D_
developed a process for purifying high titer, clinical grade Newcastle Disease virus, and apply this knowledge_x000D_
to the design, optimization and dissemination of detailed process purification protocols for production of high_x000D_
titer, clinical grade viral vaccines and gene transfer vectors using NatriFlo HD-Q membrane technology. Natrix_x000D_
Separations is a leading supplier of high performance, single use and multi-cycle chromatography products to_x000D_
the life science markets. Their membrane chromatography columns are used in a variety of applications_x000D_
including the separation and purification of peptides, proteins, nucleic acids, and monoclonal antibodies. To_x000D_
grow their business, Natrix is seeking to broaden their patented separation technology platform to include_x000D_
purification of clinical grade viral vaccines/vectors and oncolytic viruses for use in humans and animals. While_x000D_
Natrix has the chromatographic devices and process development expertise, they do not have the infrastructure_x000D_
(CL2 lab and animal facilities, access to viruses) or the virology expertise necessary to conduct these_x000D_
experiments. Therefore, it is absolutely critical that Natrix partner with an academic virology lab to develop_x000D_
virus-specific purification processes and evaluate the activity and purity of the final product in an animal_x000D_
model. Indeed, that was the premise of our initial NSERC Engage grant. Due to the tremendous success of this_x000D_
collaboration, we are now applying for funding to develop and test anion exchange and affinity_x000D_
chromatography-based purification processes for a variety of clinically relevant viral vaccines and viral vectors., program purpose french : Viruses engineered to express antigens to promote a protective immune response against a particular pathogen_x000D_
(vaccine), or to deliver a therapeutic gene (gene therapy) or to treat cancer (oncolytic virotherapy) are essential_x000D_
tools used in the prevention and treatment of diseases in humans and animals. However, a considerable_x000D_
impediment to the use of viruses as vaccines or therapeutic agents is the availability of efficient, scalable_x000D_
purification systems. The goal of this project is to build upon the process development expertise acquired_x000D_
during our initial NSERC Engage funded collaboration with Natrix Separations, in which we successfully_x000D_
developed a process for purifying high titer, clinical grade Newcastle Disease virus, and apply this knowledge_x000D_
to the design, optimization and dissemination of detailed process purification protocols for production of high_x000D_
titer, clinical grade viral vaccines and gene transfer vectors using NatriFlo HD-Q membrane technology. Natrix_x000D_
Separations is a leading supplier of high performance, single use and multi-cycle chromatography products to_x000D_
the life science markets. Their membrane chromatography columns are used in a variety of applications_x000D_
including the separation and purification of peptides, proteins, nucleic acids, and monoclonal antibodies. To_x000D_
grow their business, Natrix is seeking to broaden their patented separation technology platform to include_x000D_
purification of clinical grade viral vaccines/vectors and oncolytic viruses for use in humans and animals. While_x000D_
Natrix has the chromatographic devices and process development expertise, they do not have the infrastructure_x000D_
(CL2 lab and animal facilities, access to viruses) or the virology expertise necessary to conduct these_x000D_
experiments. Therefore, it is absolutely critical that Natrix partner with an academic virology lab to develop_x000D_
virus-specific purification processes and evaluate the activity and purity of the final product in an animal_x000D_
model. Indeed, that was the premise of our initial NSERC Engage grant. Due to the tremendous success of this_x000D_
collaboration, we are now applying for funding to develop and test anion exchange and affinity_x000D_
chromatography-based purification processes for a variety of clinically relevant viral vaccines and viral vectors., agreement title english : Optimization of scalable chromatography-based purification methods utilizing NatriFlo HD-Q_x000D_
membrane technology for downstream processing of viral vaccines and viral vectors, agreement title french : Optimization of scalable chromatography-based purification methods utilizing NatriFlo HD-Q_x000D_
membrane technology for downstream processing of viral vaccines and viral vectors, agreement number : EGP2, agreement value : 11910.0, agreement start date : 2017-10-18, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada